Many patients with DPB suffer from chronic cough, copious sputum, and exertional dyspnoea, and have bilateral small nodular shadows and hyperinflation of the lungs on chest radiography.'"3 The major symptom of COPD is exertional dyspnoea, and many patients complain of productive cough. In addition, both diseases are characterised by chronic airflow limitation. These two diseases therefore show some similarity in their clinical presentation.
Results -Baseline FEV1 was similar in the two groups of patients. Patients with COPD were more responsive to methacholine than were those with DPB (geometric mean PD20FEV, 8-87 v cumulative units). Reversibility of air flow obstruction, expressed as the difference between the percentage predicted postbronchodilator FEV, and prebronchodilator FEVy, was significantly larger in patients with COPD than in those with DPB (7-87 (6-52)% v [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] (4*43)%).
Conclusions -The observation that patients with DPB differ substantially in bronchial responsiveness from those with COPD is thought to reflect the difference in the mechanisms of these two diseasesthat is, airway disease in DPB and more parenchymal disease in the group of patients with COPD. The nature of bronchiolar inflammation in COPD and DPB is also different, possibly explaining the difference in bronchial responsiveness.
More fixed airflow limitation as a result of structural bronchiolar lesions in DPB will explain the smaller reversiblity of airflow obstruction.
(Thorax 1994;49:540-544) Diffuse panbronchiolitis (DPB) is characterised clinically by chronic airflow limitation and lower respiratory tract infection often associated with paranasal sinusitis. Pathologically it is a chronic inflammatory disease of the airways and the predominant sites are the bronchiolar and centrilobular regions.`13 This disease was first described in 1969, and many patients with DPB have since been reported, predominantly in Japan, with several cases elsewhere.' On the other hand, chronic obstructive pulmonary disease (COPD) is defined as a disorder characterised by an abnormality of expiratory flow that does not change markedly over periods of several months.7 The pathology of COPD is described as a mixture of inflammation of the central and peripheral airways and emphysema to varying degrees.8 Chronic inflammatory changes related to prolonged cigarette consumption are accepted as the primary cause of these pathological changes. 9 Many patients with DPB suffer from chronic cough, copious sputum, and exertional dyspnoea, and have bilateral small nodular shadows and hyperinflation of the lungs on chest radiography.'"3 The major symptom of COPD is exertional dyspnoea, and many patients complain of productive cough. In addition, both diseases are characterised by chronic airflow limitation. These two diseases therefore show some similarity in their clinical presentation.
Bronchial hyperresponsiveness to nonspecific stimuli is a feature of COPD, and increased bronchial responsiveness is associated with the accelerated annual decline of FEV1, even after adjusting for the baseline level of lung function.'0'I The acute bronchodilator response has also been shown to correlate with prognosis.'0 These observations may reflect an important relation between functional or structural abnormalities, or both, and the pathogenesis of bronchial hyperresponsiveness and bronchodilator response in COPD.
To elucidate the functional differences between COPD and DPB we have evaluated the bronchial responsiveness and bronchodilator response in patients with these diseases. 
Results
Seventy five patients with COPD and 51 patients with DPB were included in the study. Baseline pulmonary function and other characteristics are summarised in table 1. Airway resistance and RV/TLC were in the same range for both diseases. Both groups of patients had similar serum IgE levels. All of the patients with COPD were smokers as a smoking history was an entry criterion. On the other hand, 78% of patients with DPB had never smoked.
Bronchial FEV1 (I) Figure 2 Relation between baseline FEV, and bronchial responsiveness to methacholine in patients with diffuse panbronchiolitis. rs = 0 414, p < 0°05.
rs=O-414, p < 0 05). There were significant differences in intercepts (-0-168 v 1-331, p<0-001) and slopes (0807 v 0-209, p<0-01) between these two regression lines. There were no significant correlations between baseline FEV1 and bronchodilator response in patients with either disease. Most of the patients with COPD in our study had CT findings compatible with emphysema, probably because few patients with COPD in Japan have predominantly intrinsic airways disease without significant emphysema. Thus, there might be racial differences in the effects of smoking related airway inflammation causing a variable pattern in chronic bronchitis in our country.
In conclusion, our observation that patients with DPB differ substantially in bronchial responsiveness and bronchodilator response from those with COPD is thought to reflect the distinct mechanisms of these two diseasesthat is, airway disease in DPB and parenchymal disease in COPD with emphysema. The nature of bronchiolar inflammation in COPD and DPB is also quite different, possibly explaining the difference in bronchial hyperresponsiveness.
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